Is the survival advantage gained by the addition of bevacizumab to chemotherapy for the treatment of recurrent, persistent, or advanced cervical cancer worth the additional cost? A cost-effectiveness analysis

✍ Scribed by Schroeder, E.D.; Burbano-Levy, X.; De La Garza, J.; Garcia-Soto, A.E.; Hew, K.E.; Andrade, F.; Simpkins, F.; Pearson, J.M.; Lucci, J.A.; Diaz, J.P.

• Book ID: 127265218
• Publisher: Elsevier Science
• Year: 2014
• Tongue: English
• Weight: 80 KB
• Volume: 133
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2014.03.386